Actoplus Met Overview

10Views

Feature	Description
Active Ingredients	Pioglitazone, Metformin
Available Dosages	15 mg/500 mg, 15 mg/850 mg
Formulation	Oral Tablets
Indication	Type 2 Diabetes Mellitus
Important Note	Consult healthcare professional before use
Learn More About Actoplus Met

Chemical Structure

The medication known as Actoplus Met is a combination therapy. It integrates two active substances: pioglitazone and metformin. Pioglitazone belongs to the thiazolidinedione class. Its structure is characterized by a thiazole ring linked to a pyridine ring. This configuration contributes to its efficacy in reducing insulin resistance. Metformin, classified as a biguanide, contains a guanidine group and an alkyl chain. This simple structure aids its role in decreasing glucose production in the liver. When these components come together, they form a potent combination for managing blood sugar levels in Type 2 Diabetes.

Dosage Information

Actoplus Met 15 mg/500 mg and 15 mg/850 mg are two primary dosage forms. Initiation typically begins with the lower dosage. Adjustment depends on individual response and tolerance. It is crucial to ingest the tablets with meals. This minimizes gastrointestinal side effects often associated with metformin. Regular monitoring of blood glucose levels ensures the dosage meets therapeutic targets. Medical professionals must guide any alteration in dosage. Discontinuation requires professional consultation to avoid abrupt blood glucose changes.

Indications

Type 2 Diabetes Mellitus is the primary indication for Actoplus Met. It is prescribed when monotherapy does not suffice. The dual mechanism of action improves glycemic control. Metformin decreases hepatic glucose production. Pioglitazone enhances insulin sensitivity. This combination targets key aspects of the disease’s pathophysiology. It is not indicated for Type 1 Diabetes or diabetic ketoacidosis. Patients with active liver disease or severe renal impairment should avoid this medication.

Pregnancy and Breastfeeding

The safety of Actoplus Met in pregnancy remains uncertain. Animal studies show adverse effects on the fetus with pioglitazone. Human data is limited. Metformin crosses the placenta. It is crucial to weigh potential risks and benefits with healthcare professionals. During breastfeeding, metformin appears in breast milk. The effects on nursing infants are not well documented. Consultation is vital for those considering or continuing Actoplus Met during pregnancy or lactation.

Toxicity

Overdose of Actoplus Met can lead to lactic acidosis due to metformin. Symptoms include malaise, myalgia, respiratory distress, and hypothermia. Pioglitazone overdose symptoms are less defined but may cause hypoglycemia. Immediate medical intervention is crucial. Management involves supportive measures and monitoring of lactic acid levels. The combination’s toxicity emphasizes the need for adherence to prescribed dosages and regular medical check-ups.

For further reading, consider visiting Drugs.com for comprehensive drug information.

Side Effects	Common Symptoms
Gastrointestinal	Nausea, diarrhea
Musculoskeletal	Joint pain
Metabolic	Hypoglycemia

Actoplus Met targets two key pathways: insulin resistance and glucose production.
Regular blood tests are crucial to monitor efficacy and safety.
Patient adherence to prescribed regimens enhances therapeutic outcomes.

Primary source:

Actoplus Met Overview